Tissue Regenix appoints Jonathan Glenn as permanent Non-Executive Chairman

– UK, Leeds –  Tissue Regenix Group PLC (LON: TRX), the regenerative medical devices company, today announced the appointment of Jonathan Glenn, current Interim Non-Executive Chairman, to the position of Non-Executive Chairman with immediate effect.

Jonathan joined the Group in January 2016 and was appointed Interim Non-Executive Chairman in March 2020.

“We are delighted to have Jonathan appointed as Non-Executive Chairman to the Group. Jonathan’s leadership has been invaluable over the last year, as Interim Chairman, and we look forward to his continued contribution towards the Company’s future growth.” said CEO, Daniel Lee.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement, and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight’s human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

For more information: https://www.tissueregenix.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.